These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 15149035)

  • 1. Bordetella pertussis from functional genomics to intranasal vaccination.
    Locht C; Antoine R; Raze D; Mielcarek N; Hot D; Lemoine Y; Mascart F
    Int J Med Microbiol; 2004 Apr; 293(7-8):583-8. PubMed ID: 15149035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attenuated Bordetella pertussis BPZE1 as a live vehicle for heterologous vaccine antigens delivery through the nasal route.
    Li R; Lim A; Alonso S
    Bioeng Bugs; 2011; 2(6):315-9. PubMed ID: 22067832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction and preliminary immunobiological characterization of a novel, non-reverting, intranasal live attenuated whooping cough vaccine candidate.
    Cornford-Nairns R; Daggard G; Mukkur T
    J Microbiol Biotechnol; 2012 Jun; 22(6):856-65. PubMed ID: 22573165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Engineering of attenuated Bordetella pertussis bacteria producing immunogenic non-toxic form of pertussis toxin].
    Siniashina LN; Nechaeva EV; Amelina IP; Karataev GI
    Zh Mikrobiol Epidemiol Immunobiol; 2009; (6):89-94. PubMed ID: 20095432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuated Bordetella pertussis: new live vaccines for intranasal immunisation.
    Mielcarek N; Debrie AS; Raze D; Quatannens J; Engle J; Goldman WE; Locht C
    Vaccine; 2006 Apr; 24 Suppl 2():S2-54-5. PubMed ID: 16823926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Construction of the genetically attenuated bacteria Bordetella pertussis devoid of dermonecrotic toxin activity and producing modified nontoxic pertussis toxin form].
    Siniashina LN; Siniashina LS; Semin EG; Amelina IP; Karataev GI
    Mol Gen Mikrobiol Virusol; 2010; (3):31-6. PubMed ID: 20886687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3.
    Debrie AS; Coutte L; Raze D; Mooi F; Alexander F; Gorringe A; Mielcarek N; Locht C
    Vaccine; 2018 Mar; 36(11):1345-1352. PubMed ID: 29433898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The BvgAS Regulon of
    Moon K; Bonocora RP; Kim DD; Chen Q; Wade JT; Stibitz S; Hinton DM
    mBio; 2017 Oct; 8(5):. PubMed ID: 29018122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal Immunization with Acellular Pertussis Vaccines Results in Long-Term Immunity to Bordetella pertussis in Mice.
    Wolf MA; Boehm DT; DeJong MA; Wong TY; Sen-Kilic E; Hall JM; Blackwood CB; Weaver KL; Kelly CO; Kisamore CA; Bitzer GJ; Bevere JR; Barbier M; Damron FH
    Infect Immun; 2021 Feb; 89(3):. PubMed ID: 33318136
    [No Abstract]   [Full Text] [Related]  

  • 10. Is there a need for a new generation of vaccines against pertussis?
    Storsaeter J; Wolter J
    Expert Opin Emerg Drugs; 2006 May; 11(2):195-205. PubMed ID: 16634696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Mucosal Immunity in Pertussis.
    Solans L; Locht C
    Front Immunol; 2018; 9():3068. PubMed ID: 30692990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective role of adenylate cyclase in the context of a live pertussis vaccine candidate.
    Lim A; Ng JK; Locht C; Alonso S
    Microbes Infect; 2014 Jan; 16(1):51-60. PubMed ID: 24140230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice.
    Mielcarek N; Debrie AS; Mahieux S; Locht C
    Clin Vaccine Immunol; 2010 Mar; 17(3):317-24. PubMed ID: 20107007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of vaccines against pertussis caused by Bordetella holmesii using a mouse intranasal challenge model.
    Saito M; Odanaka K; Otsuka N; Kamachi K; Watanabe M
    Microbiol Immunol; 2016 Sep; 60(9):599-608. PubMed ID: 27515393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1.
    Feunou PF; Kammoun H; Debrie AS; Mielcarek N; Locht C
    Vaccine; 2010 Oct; 28(43):7047-53. PubMed ID: 20708998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular aspects of Bordetella pertussis pathogenesis.
    Locht C
    Int Microbiol; 1999 Sep; 2(3):137-44. PubMed ID: 10943406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.
    Dorji D; Mooi F; Yantorno O; Deora R; Graham RM; Mukkur TK
    Med Microbiol Immunol; 2018 Feb; 207(1):3-26. PubMed ID: 29164393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigating pertussis toxin and its impact on vaccination.
    Coutte L; Locht C
    Future Microbiol; 2015; 10(2):241-54. PubMed ID: 25689536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough.
    Mielcarek N; Debrie AS; Raze D; Bertout J; Rouanet C; Younes AB; Creusy C; Engle J; Goldman WE; Locht C
    PLoS Pathog; 2006 Jul; 2(7):e65. PubMed ID: 16839199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global population structure and evolution of Bordetella pertussis and their relationship with vaccination.
    Bart MJ; Harris SR; Advani A; Arakawa Y; Bottero D; Bouchez V; Cassiday PK; Chiang CS; Dalby T; Fry NK; Gaillard ME; van Gent M; Guiso N; Hallander HO; Harvill ET; He Q; van der Heide HG; Heuvelman K; Hozbor DF; Kamachi K; Karataev GI; Lan R; Lutyńska A; Maharjan RP; Mertsola J; Miyamura T; Octavia S; Preston A; Quail MA; Sintchenko V; Stefanelli P; Tondella ML; Tsang RS; Xu Y; Yao SM; Zhang S; Parkhill J; Mooi FR
    mBio; 2014 Apr; 5(2):e01074. PubMed ID: 24757216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.